Contact with business partners in the world of dentistry.

First sales will occur in 2025. WaveImplant will market this medical device in France directly, by setting up a small appropriate sales force. In France, we will initially target key dental implantology centers (B2C). In parallel, we will position OsteoWave abroad, under license agreements with one or more heavyweights of the dental implantology sector.

Only OsteoWave allows an access to the biomechanical properties and features of the bone-implant interface that drive surgical success or failure. Due to the very random performance of Osstell device, the most widely used clinical method remains the dental surgeon proprioception. OsteoWave will thus make it possible to guide the surgeon as to the decision to proceed with immediate loading and to detect early signs of periimplantitis.

Only OsteoWave allows an access to the biomechanical properties and features of the bone-implant interface that drive surgical success or failure. Due to the very random performance of Osstell device, the most widely used clinical method remains the dental surgeon proprioception. OsteoWave will thus make it possible to guide the surgeon as to the decision to proceed with immediate loading and to detect early signs of periimplantitis.